# Boston Scientific (BSX) has become quite toxic for shareholders.

*biotech · news · 2026-04-28 · Barchart*

## Key points

- Boston Scientific stock fell over 37% in 2024, erasing late-2023 gains.
- The $374-per-share Penumbra acquisition faces integration friction and caused shareholder valuation concerns.
- Boston Scientific is losing market share in pulsed field ablation due to increased competition.
- A Markovian induction model suggests a 54.1% chance BSX will rise after recent bearish signals.
- Forward distribution projects BSX could reach $59–$64 in 10 weeks, peaking near $62.

**Companies:** Boston Scientific, Penumbra
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1561248/massively-disappointing-boston-scientific-bsx-stock-could-be-due-for-a-comeback)

---

Canonical: https://newsio.io/n/36c048fd-0d0f-4b5a-b93d-3740db718ae5/boston-scientific-bsx-has-become-quite-toxic-for-shareholders-since-the-beginnin
Summarized by Newsio from Barchart. https://newsio.io/how-it-works